Advanced Emissions Solutions provides emissions reductions technologies through consumables that utilize powdered activated carbon (PAC) and chemical based technologies, primarily serving the coal-fired power generation and industrial boiler industries. The company's operations consisted of two reportable segments: refined coal, which engages in equity method investments as well as royalty related to reduced emissions of both nitrogen oxide and mercury from coal; and Power Generation and Industrials, which sells consumable products that utilize PAC and chemical technologies as well as historically the sale of activated carbon injection and dry sorbent injection equipment systems.

Ameresco provides energy services, including infrastructure upgrades, energy security, asset sustainability and renewable energy solutions throughout North America and Europe. The company's sustainability services include capital and operational upgrades to a facility's energy infrastructure and the development, construction, ownership and operation of renewable energy plants. The company's principal service is energy projects, which entails the design, engineering and installation of, and assisting with the arranging of financing for an array of technologies and techniques to improve the usage of energy, and control the operation, of a building's energy- and water- consuming systems.

Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The company's products are sold worldwide, primarily to wholesalers, specialty distributors, retail pharmacies, hospitals, government entities and the medical profession. The company manufactures products in the United States and Puerto Rico and has manufacturing operations in two foreign countries. The company has products in the following therapeutic classes: hematology, oncology, cardiovascular and immunology. The company's pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics.

CommScope Holding is a provider of infrastructure solutions for communication networks. The company's solutions and services for wired and wireless networks enable high-bandwidth data, video and voice applications. The company's operating segments are: CommScope Connectivity Solutions (CCS) and CommScope Mobility Solutions (CMS). The CCS segment is engaged in providing fiber optic and copper connectivity solutions for use in data centers and business enterprise, telecommunications, cable television and residential broadband networks. The CMS segment is engaged in providing infrastructure for wireless networks.

Heron Therapeutics is a commercial-stage biotechnology company. The company is developing patient-focused solutions that apply its science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. The company develops SUSTOL for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide combination chemotherapy regimens. The company's second commercial product, CINVANTI, is indicated for the prevention of acute and delayed nausea and vomiting associated with of highly emetogenic cancer chemotherapy and nausea and vomiting associated with MEC.

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic and liver diseases. The company's main product candidate, MGL-3196 (resmetirom), is a proprietary, orally administered, small molecule, liver-directed, thyroid hormone receptor-? selective agonist being developed as a once-daily oral pill that can potentially be used to treat a number of disease states including non-alcoholic steatohepatitis.